

# The Effects of Valproic Acid on Viability of MCF-7 Cell Line

Naji T, Zakeri Ghaderi, Erfani M\*

Tahereh Naji (PhD, Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences & Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran-Iran (IAUPS).

Marzieh Zakeri Ghaderi, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran-Iran (IAUPS).

Mino Erfani (\*corresponding author), Department of Biochemistry, Faculty of Advanced Sciences & Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran-Iran (IAUPS)

**Abstract:** Valproic acid is used in the epilepsy, bipolar and migraine therapy. As a histone deacetylase inhibitor, valproic acid has been recently under investigation in cancer treatment. This study was done to determine the effect of valproic acid on viability of MCF-7 breast cancer cell line. In this experimental study, MCF-7 cell line was obtained from the Iranian Pasteur Institute. The cells were treated and incubated by different concentrations of valproic acid (1, 2, 4, 8, 16, 32 and 64 mM). Cell viability was evaluated with trypan blue staining. There was a significant dose-dependent correlation between reduction of MCF7 cell viability with valproic acid concentration ( $P < 0.05$ ). Valproic acid caused a significant decline in the viability of MCF-7 breast cancer cell line.

**Keywords:** Breast cancer, MCF-7, Valproic acid, Viability..

## 1. Introduction

Breast cancer is a complex disease that genetic and environmental factors contribute a lot in it. Chance of getting breast cancer goes up with age. In addition, female gender is a risk factor for breast cancer. Breast cancer is the most common cancer in women after skin cancer (non-melanoma) and the second leading cause of death cancer in women after lung cancer. Women's risk of developing invasive breast cancer in women is about 13 percent [1]. Nowadays, for breast cancer treatment methods such as surgery, chemotherapy and radiation therapy are used [2]. Valproic acid is an inhibitor of histone deacetylase that in treating certain types of epilepsy and depression is used [3]-[5]. This compound has been studied as an anti-cancer agent that can be used both alone and in combination with other conventional cancer treatments such as chemotherapy and radiation [6]-[8]. However, some studies have shown that valproic acid protective effect against apoptosis in some of cancer cells creates that is still not known of the mechanism [9]. Given the widespread prevalence of breast cancer and the importance of dealing with it, further studies are necessary to discover new anticancer drugs and compounds that can increase the effectiveness and to reduce possible side effects. This study was carried out to determine the effect of Valproic acid on viability of MCF-7 breast Cancer cell line, and the results of this study will be useful in the treatment of breast Cancer.

## 2. Material and Method

In this study, MCF-7 cell line in growing was obtained from the Iranian Pasteur Institute. Cells were placed in, incubator 37 ° C and 95% humidity and carbon dioxide 5%. After counting cells under a microscope by Neubauer slide, 5000 cells were transferred to plate. The cells were treated and incubated by different concentrations of valproic acid (1, 2, 4, 8, 16, 32 and 64 mM). Cell viability was evaluated with trypan blue staining. Data were analyzed using ANOVA.

### 3. Results

Figure I shows MCF7 cell viability at different concentrations (1, 2, 4, and 8 mM) of valproic acid at different periods (24, 48, and 72 h).




Fig. 1: Viability of MCF-7 cell Line compared to control group.

Our results indicated that 2, 4 and 8 mM of valproic acid started to exert significant cytotoxic effects on MCF7 cells exert 48 hours after incubation show ( $P < 0.05$ ).

### 4. Discussion

The results of this study showed that appropriate doses of valproic acid caused a significant decline in viability of MCF-7 breast cancer cell line. In this regard, in study Byun and et al, valproic acid therapy resulted in a significant decrease leading to a significant reduction in colony -forming ability and cell invasion , and the effect of the drug in different types of medication were different [10]. Our results are also consistent with the results of Arakawa and et al, showing that the use of valproic acid can stop the cell cycle in phase G1, and stop cell proliferation. The effectiveness of valproic acid in cancer cells sensitive to estrogen also has been established[11]. There are also studies showing that simultaneous use of valproic acid and anticancer drugs induces apoptosis in various cancer cells [11], [12].

### 5. Conclusion

The results of this study showed that valproic acid caused a significant decline in viability of MCF-7 breast cancer cell line.

### 6. Acknowledgment

We appreciate all who helped us to exert the present study. This paper reports a part of results selected from research work carried out by Marzieh Zakeri Ghaderi supervised by Dr. J Asadi and consulted by Dr. T. Naji at Advanced Sciences & Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran-Iran (IAUPS).

### 7. References

- [1] Armstrong K1, Eisen A, Weber B. Assessing the risk of breast cancer. *N Engl J Med.* 2000 Feb 24; 342(8):564-71. <http://dx.doi.org/10.1056/NEJM200002243420807>

- [2] Hosseinimehr SJ. Trends in the development of radioprotective agents. *Drug Discov Today*. 2007 Oct; 12(19-20):794-805.  
<http://dx.doi.org/10.1016/j.drudis.2007.07.017>
- [3] Karagiannis TC1, Kn H, El-Osta A. The epigenetic modifier, valproic acid, enhances radiation sensitivity. *Epigenetics*. 2006 Jul-Sep; 1(3):131-7. Epub 2006 May 17.  
<http://dx.doi.org/10.4161/epi.1.3.2896>
- [4] Rabbani-Chadegani A1, Chamani E, Hajihassan Z. The effect of vinca alkaloid anticancer drug, vinorelbine, on chromatin and histone proteins in solution. *Eur J Pharmacol*. 2009 Jun 24; 613(1-3):34-8.  
<http://dx.doi.org/10.1016/j.ejphar.2009.04.040>
- [5] Mologni L1, Cleris L, Magistrone V, Piazza R, Boschelli F, Formelli F, et al. Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. *Int J Cancer*. 2009 Apr 15; 124(8):1990-6.  
<http://dx.doi.org/10.1002/ijc.24158>
- [6] Harikrishnan KN1, Karagiannis TC, Chow MZ, El-Osta A. Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments. *Cell Cycle*. 2008 Feb 15; 7(4):468-76.  
<http://dx.doi.org/10.4161/cc.7.4.5405>
- [7] Debeb BG1, Xu W, Mok H, Li L, Robertson F, Ueno NT, et al. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. *Int J Radiat Oncol Biol Phys*. 2010 Mar 1; 76(3):889-95.  
<http://dx.doi.org/10.1016/j.ijrobp.2009.09.052>
- [8] Karagiannis TC1, El-Osta A. Modulation of cellular radiation responses by histone deacetylase inhibitors. *Oncogene*. 2006 Jun 29; 25(28):3885-93.  
<http://dx.doi.org/10.1038/sj.onc.1209417>
- [9] Uo T1, Veenstra TD, Morrison RS. Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. *J Neurosci*. 2009 Mar 4; 29(9):2824-32.  
<http://dx.doi.org/10.1523/JNEUROSCI.6186-08.2009>
- [10] Byun SS1, Kim FJ, Khandrika L, Kumar B, Koul S, Wilson S, et al. Differential effects of valproic acid on growth, proliferation and metastasis in HTB5 and HTB9 bladder cancer cell lines. *Cancer Lett*. 2009 Aug 28; 281(2):196-202.  
<http://dx.doi.org/10.1016/j.canlet.2009.02.045>
- [11] Arakawa Y1, Saito S, Yamada H, Aiba K. Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-X(L) and promotes apoptosis of MCF-7 breast cancer cells. *Apoptosis*. 2009 Sep; 14(9):1076-85.  
<http://dx.doi.org/10.1007/s10495-009-0384-0>
- [12] Vandermeers F1, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. *Clin Cancer Res*. 2009 Apr 15; 15(8):2818-28.  
<http://dx.doi.org/10.1158/1078-0432.CCR-08-1579>